Miscellaneous Immune Disorders
EGPA (formerly known as Churg-Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils (a type of white blood cell that helps fight infection), and inflammation of small- to medium-sized blood vessels.
The researchers found that among 495 patients with undetectable CMV DNA at randomization, fewer patients in the letermovir group had clinically significant CMV infection or were classified as having a primary end point event by week 24 after transplantation, compared with the placebo group.
Prevymis, a non-nucleoside CMV inhibitor (3,4 dihydro-quinazoline), inhibits viral replication through targeting the viral terminase complex.
Most patients were asymptomatic and the diagnosis was discovered in pursuit of other abnormal biochemical tests and imaging studies. In the majority of patients, alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) were elevated (88 and 90%, respectively).
In the study, Actemra given weekly and bi-weekly combined with a 6-month glucocorticoid regimen, more effectively sustained remission through Week 52 than placebo combined with a 26-week steroid taper and a 52-week steroid taper.
Based on the lab findings, a clinical trial testing bestatin against lymphedema is underway, Dr. Stanley Rockson lead author of the research.
For each of the five studies, researchers found a potential for bias through conducting a 'Risk of bias' assessment; none of the trials were deemed 'high quality'
The FDA has granted Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations for the investigational tissue-based therapy, RVT-802 (Enzyvant), for the treatment of complete DiGeorge Syndrome (cDGS).
Rigel announced its submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenic purpura (ITP).
A trial involving 93 eosinophilic esophagitis patients aged 11 to 40 years with dysphagia were randomly allocated to receive either budesonide oral suspension or placebo twice daily.
Genentech announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
Holy basil is not recommended for pregnant or nursing mothers or young children. It should also be used with caution in patients with diabetes.
Genentech has announced that the Food and Drug Administration (FDA) has accepted the company's Supplmental New Drug Application (sBLA) for Actemra (tocilizumab) to treat giant cell arteritis (GCA).
Use of hydrolyzed cow's milk-based formula introduced during the first seven days is associated with increased risk of islet autoimmunity in infants at increased risk of type 1 diabetes (T1D), according to a study published online in Diabetes Care.
Just 20 minutes of moderate exercise may reduce inflammation in the body, according to research published online recently in Brain, Behavior, and Immunity.
Lortholary, O, Chandesris, MO, Livideanu CB, et al. "Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study."
Long-term safety and efficacy data from a continuation study of Benlysta in patients with systemic lupus erythematosus (SLE) has been released.
Giant cell arteritis is a chronic, potentially life-threatening autoimmune condition that is more likely to affect women than men.
The Food and Drug Administration (FDA) has granted three approvals for the expanded use of Ilaris (canakinumab; Novartis) for patients with rare Periodic Fever Syndrome conditions.
The FDA has granted Orphan Drug designation to nintedanib (Boehringer Ingelheim) for the treatment of systemic sclerosis (SSc, or scleroderma), including the associated interstitial lung disease (SSc-ILD).
The FDA has granted Orphan Drug designation to TG-1101 (ublituximab; TG Therapeutics) for the treatment of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD).
The FDA has granted Orphan Drug designation to dusquetide (SGX942; Soligenix) for the treatment of macrophage activation syndrome (MAS), a life-threatening complication of rheumatic disease.